
2025 ACC statement: inflammation is actionable in CVD, with universal hsCRP screening
Summarises the 2025 ACC Scientific Statement (JACC) concluding the inflammation-ASCVD link is now clinically actionable. It recommends universal hsCRP screening in primary and secondary prevention alongside cholesterol, notes IL-6 and fibrinogen also predict risk, and says CT perivascular fat attenuation is promising but not routine. It contrasts this with a more cautious 2002 CDC/AHA workshop.


